Publications

The societal costs of metachromatic leukodystrophy (MLD) in the United States

Bean K, Miller B, Jensen I, Howle K, Wilds A, Walz M, et al. The societal costs of metachromatic leukodystrophy (MLD) in the United States. Abstract EE547, ISPOR EU 2023.

Cost-consequence of cladribine tablets for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in the UK

Miller B, Russel-Szymczyk M, Jensen I, Shah A, Alexopoulos T, Herbert A, et al. Cost-consequence of cladribine tablets for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in the UK. Abstract EE658, ISPOR EU 2023.

A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV Plus for the diagnosis of viral respiratory infections from a US health plan perspective

Davies S, Boller E, Beaubrun A, Miller C, Jensen I. A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV Plus for the diagnosis of viral respiratory infections from a US health plan perspective. Abstract ID309. AMP 2023 Annual Meeting & Expo.

Prevalence of acute uncomplicated cystitis in Japan.

Franklin M, Emden MR, Bauer E, Nguyen AT, Sacks N, Kawamatsu S, Kawano Y,  Mitrani-Gold FS, Joshi AV, Ju S, Preib MT. Prevalence of acute uncomplicated cystitis in Japan. Poster presentation, IDWeek, October 2023.

Cost burden of patients with oral antibiotic treatment failure for uncomplicated urinary tract infection in the United States.

Franklin M, Emden MR, Kautz S, Nguyen AT, Sacks NC, Ju S, Mitrani-Gold FS, Joshi AV, Preib MT. Cost burden of patients with oral antibiotic treatment failure for uncomplicated urinary tract infection in the United States. Poster presentation, IDWeek, October 2023.

Health care resource utilization and costs in patients with painful diabetic neuropathy treated with 10 kHz spinal cord stimulation therapy

Taylor RS, Lad SP, White JL, Stauss TG, Healey BE, Sacks NC, McLin R, Patil S, Jaasma MJ, Caraway DL Petersen EA. 2023. Health care resource utilization and costs in patients with painful diabetic neuropathy treated with 10 kHz spinal cord stimulation therapy. J Manag Care Spec Pharm 29(9):1021-1029; doi: 10.18553/jmcp.2023.29.9.1021. PMID: 37610114.

Scoping review of employer-led research using employee health claims data

Movva N, Pastula ST, Rege SV, Lewis RJ, Bylsma LC. 2023. Scoping review of employer-led research using employee health claims data. Popul Health Manag 26(5):341-352; doi: 10.1089/pop.2023.0140. PMID: 37682577.

Point of care analysis for men with adrenomyeloneuropathy: A retrospective study of real world data

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr PL, Sawyer EK, Stephen CD, Eichler F. Point of care analysis for men with adrenomyeloneuropathy: A retrospective study of real world data. Poster presentation, European Academy of Neurology, Budapest, Hungary, July 2023.

Healthcare utilization, burden of illness, and mortality in adults with adrenomyeloneuropathy: The case for genetic therapies

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen CD, Eichler F. Healthcare utilization, burden of illness, and mortality in adults with adrenomyeloneuropathy: The case for genetic therapies. Poster presentation, American Society of Cell and Gene Therapy Meeting, Los Angeles, CA, May 2023.

Health disparities among patients with schizophrenia in an integrated healthcare system.

Seo S, Healey B,  McLin R, Sacks N,  Benson C, Citrome L. Health disparities among patients with schizophrenia in an integrated healthcare system. Poster presentation, Psych Congress Elevate 2023, May 30-June 2, 2023.

Estimating the lifetime burden of illness in patients with bronchiolitis obliterans syndrome

Jensen I, Srivastava K, Minshall M, Kemp R. Estimating the lifetime burden of illness in patients with bronchiolitis obliterans syndrome. Abstract EE539, ISPOR 2023.

Evaluating the face validity of health state utility values (HSUVS) for metachromatic leukodystrophy (MLD)

Bean K, Miller B, Jensen I, Fields C, Pang F. Evaluating the face validity of health state utility values (HSUVS) for metachromatic leukodystrophy (MLD). Abstract EE285, ISPOR 2023.

Direct cost analysis associated with the management of patients with metachromatic leukodystrophy (MLD) across nine European countries

Bean K, Olaye A, Miller B, Jensen I, Dean R, Pang F. Direct cost analysis associated with the management of patients with metachromatic leukodystrophy (MLD) across nine European countries. Abstract EE408, ISPOR 2023.

Substantial burden of illness and mortality in men with adrenomyeloneuropathy

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen CD, Eichler F. Substantial burden of illness and mortality in men with adrenomyeloneuropathy. Poster presentation at American Academy of Neurology Annual Meeting, April 2023.

The cost of non-cystic fibrosis bronchiectasis (NCFB) in patients with commercial insurance or Medicare coverage in the US

Minshall M, Emden M, McLin R, Kemp P, Pontenani F, Cardosi L, Sacks N. The cost of non-cystic fibrosis bronchiectasis (NCFB) in patients with commercial insurance or Medicare coverage in the US. Poster presentation, ISPOR, April 2023.

The economic impact of adrenomyeloneuropathy (AMN) on direct medical costs in commercially insured US adults: A retrospective study

Eichler F, Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen C. The economic impact of adrenomyeloneuropathy (AMN) on direct medical costs in commercially insured US adults: A retrospective study. Poster presentation, ISPOR 27th International Meeting, Boston, MA, April 2023.

Hospitalizations, clinical characteristics and mortality in adults with adrenomyeloneuropathy (AMN): A retrospective study

Bonkowsky J, Healey B, Sacks NC, McLin R, Cyr P, Sawyer E, Stephen C. Hospitalizations, clinical characteristics and mortality in adults with adrenomyeloneuropathy (AMN): A retrospective study. Poster presentation, ISPOR 27th International Meeting, Boston, MA, April 2023.

The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US

Pang F, Dean R, Jensen I, Bean K, Fields C, Miller B. 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258.

Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A

Bullano M, Cool C, Schultz BG, Durgapal S, Sacks N, Liu Y, Kee R, Batt K. 2023. Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert Rev Phamacoecon Outcome Res 23(2):225-230; doi: 10.1080/14737167.2023.2160705. PMID: 36537696.

Healthcare resource utilization in non-cystic fibrosis bronchiectasis (NCFB) patients with commercial insurance coverage in the US